ACR 2022 Tweet by Mike Putman

I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed

Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI

Have others been using in this context or seen similar?

#ACR22 @RheumNow #ACRBest #1075